These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17687166)

  • 21. [Advanced ovarian cancer: a need for redefining therapeutic objectives and strategy].
    Bugat R; Guastalla JP; Misset JL
    Bull Cancer; 2005 Nov; 92(11):1003-6. PubMed ID: 16316835
    [No Abstract]   [Full Text] [Related]  

  • 22. [Initial treatment for ovarian cancer].
    Suzuki M; Fujiwara H; Takei Y
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):224-9. PubMed ID: 19263611
    [No Abstract]   [Full Text] [Related]  

  • 23. [Intraperitoneal chemotherapy for ovarian cancer].
    Noma J; Yoshida N
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):885-90. PubMed ID: 18633214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?
    Abou-Jawde RM; Oberoi SS
    J Clin Oncol; 2008 May; 26(15):2602-3; author reply 2603. PubMed ID: 18487582
    [No Abstract]   [Full Text] [Related]  

  • 25. Under-representation of older adults in cancer registration trials: known problem, little progress.
    Scher KS; Hurria A
    J Clin Oncol; 2012 Jun; 30(17):2036-8. PubMed ID: 22547597
    [No Abstract]   [Full Text] [Related]  

  • 26. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.
    Stuart GC; Kitchener H; Bacon M; duBois A; Friedlander M; Ledermann J; Marth C; Thigpen T; Trimble E; ;
    Int J Gynecol Cancer; 2011 May; 21(4):750-5. PubMed ID: 21543936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraperitoneal chemotherapy for women with epithelial ovarian cancer.
    Trimble EL; Thompson S; Christian MC; Minasian L
    Oncologist; 2008 Apr; 13(4):403-9. PubMed ID: 18448554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Potentialities of a cytomorphologic method in the evaluation of the efficacy of the treatment of cancer of the ovaries].
    Petrova S; Ali-zade VA
    Lab Delo; 1988; (10):31-5. PubMed ID: 2462084
    [No Abstract]   [Full Text] [Related]  

  • 29. Chemotherapy in ovarian malignancy: tumor sensitivity testing.
    Riggs JA; Jackson LG; Weiss AJ; Farell DM; Traiman R
    Obstet Gynecol; 1966 Jun; 27(6):869-74. PubMed ID: 5327493
    [No Abstract]   [Full Text] [Related]  

  • 30. Predicting ovarian tumor response.
    Foubister V
    Drug Discov Today; 2005 Mar; 10(6):380-1. PubMed ID: 15808813
    [No Abstract]   [Full Text] [Related]  

  • 31. Gynecologic oncology.
    Curr Opin Obstet Gynecol; 1993 Feb; 5(1):131-62. PubMed ID: 8425030
    [No Abstract]   [Full Text] [Related]  

  • 32. [Comparative study of results obtained by various methods of cyclophosphamide therapy in advanced cancer of the ovary].
    Krommer K; Csaba I; Keller G
    Orv Hetil; 1976; 117(20):1205-7. PubMed ID: 1272567
    [No Abstract]   [Full Text] [Related]  

  • 33. The reassessment of ovarian cancer in complete clinical remission: what are our goals?
    Clarke-Pearson DL
    Gynecol Oncol; 1994 Feb; 52(2):151-3. PubMed ID: 8314131
    [No Abstract]   [Full Text] [Related]  

  • 34. Optimal management of recurrent ovarian cancer.
    Markman M
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S40-3. PubMed ID: 19955913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer: current clinical trials.
    Coleman RL;
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S77-80. PubMed ID: 18584855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Time interval between ovarian cancer surgery and chemotherapy--secondary publication?].
    Larsen EP; Blaakaer J
    Ugeskr Laeger; 2009 Nov; 171(45):3265-8. PubMed ID: 19916194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Intraperitoneal chemotherapy in ovarian carcinoma. Life prolonging in selected patients].
    Ottevanger PB
    Ned Tijdschr Geneeskd; 2009 Mar; 153(11):503-7. PubMed ID: 19402326
    [No Abstract]   [Full Text] [Related]  

  • 38. Ovarian cancer guidelines: treatment progress and controversies.
    Morgan RJ
    J Natl Compr Canc Netw; 2011 Jan; 9(1):4-5. PubMed ID: 21233240
    [No Abstract]   [Full Text] [Related]  

  • 39. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
    Markman M
    Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.